Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 19/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.51 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3032826 | 1.00 | NPY5R (0.54) | NPY5RKCNH2HSD11B1ADRA1A | |
| SCHEMBL3032824 | 1.00 | NPY5R (0.54) | NPY5RKCNH2HSD11B1ADRA1A | |
| Lithium Ion SCHEMBL3026578 | 0.89 | NPY5R (0.52) | NPY5RKCNH2ADRA1A | |
| SCHEMBL3026756 | 0.87 | NPY5R (0.52) | NPY5RKCNH2HSD11B1 | |
| SCHEMBL3026753 | 0.87 | NPY5R (0.52) | NPY5RKCNH2HSD11B1 | |
| SCHEMBL3032395 | 0.85 | NPY5R (0.51) | NPY5RKCNH2HSD11B1ADRA1A | |
| SCHEMBL3031925 | 0.84 | NPY5R (0.48) | NPY5RKCNH2HSD11B1ADRA1A | |
| SCHEMBL3031924 | 0.84 | NPY5R (0.48) | NPY5RKCNH2HSD11B1ADRA1A | |
| SCHEMBL3038328 | 0.82 | KDM4E (0.48) | NPY5RKCNH2HSD11B1ADRA1A | |
| SCHEMBL3722689 | 0.82 | NPY5R (0.52) | NPY5RKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100216821-A1 | Benzimidazoles With A Hetero Spiro-Decane Residue As NPY-Y5 Antagonists | BARTON NICHOLAS PAUL | 2010-08-26 | — | — | US | disclosed |
| US-20100216821-A1 | Benzimidazoles With A Hetero Spiro-Decane Residue As NPY-Y5 Antagonists | BARTON NICHOLAS PAUL | 2010-08-26 | — | — | US | disclosed |
| US-20100216821-A1 | Benzimidazoles With A Hetero Spiro-Decane Residue As NPY-Y5 Antagonists | BARTON NICHOLAS PAUL | 2010-08-26 | — | — | US | disclosed |
| EP-2139861-A1 | BENZIMIDAZOLES WITH A HETERO SPIRO-DECANE RESIDUE AS NPY-Y5 ANTAGONISTS | Glaxo Group Limited (GB) | 2010-01-06 | — | — | EP | disclosed |
| WO-2008129007-A1 | BENZIMIDAZOLES WITH A HETERO SPIRO-DECANE RESIDUE AS NPY-Y5 ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216821-A1 | Benzimidazoles With A Hetero Spiro-Decane Residue As NPY-Y5 Antagonists | NPY5R, NPY4R, NPY1R | NPY5R 1/4885KCNH2 315/4885HSD11B1 1359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.